Cas-话题@MedSci

#Cas#

304篇内容 | 2812人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1624938, encodeId=a6b91624938d9, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=巨大淋巴结增生症（Castleman病）, objectType=article, longId=237268, objectId=be9c23e268af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be9c23e268af, replyNumber=0, likeNumber=65, createdTime=2021-11-07, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be9c23e268af, moduleTitle=巨大淋巴结增生症（Castleman病）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be9c23e268af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624979, encodeId=e00616249e9f6, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=全球靶向CD19 的ADC药物Loncastuximab tesirine启动关键II期研究，已完成中国临床试验首例患者给药, objectType=article, longId=217966, objectId=237d21e9664c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=237d21e9664c, replyNumber=0, likeNumber=65, createdTime=2021-10-02, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=237d21e9664c, moduleTitle=全球靶向CD19 的ADC药物Loncastuximab tesirine启动关键II期研究，已完成中国临床试验首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=237d21e9664c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624978, encodeId=36f316249e850, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=case report 第一次投cover letter 有什么建议吗？, objectType=article, longId=215633, objectId=4eb921563302, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4eb921563302, replyNumber=0, likeNumber=63, createdTime=2021-08-14, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4eb921563302, moduleTitle=case report 第一次投cover letter 有什么建议吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4eb921563302)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624977, encodeId=e00e16249e791, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle= ACAS应该选择BMT还是CEA/CAS？, objectType=article, longId=215512, objectId=cc3e2155120c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc3e2155120c, replyNumber=0, likeNumber=75, createdTime=2021-08-11, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc3e2155120c, moduleTitle= ACAS应该选择BMT还是CEA/CAS？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc3e2155120c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624976, encodeId=42a416249e63e, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=NEJM：采用CRISPR-Cas9进行在体基因编辑治疗转甲状腺素蛋白淀粉样变性, objectType=article, longId=215474, objectId=cc6f2154e469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc6f2154e469, replyNumber=0, likeNumber=117, createdTime=2021-08-10, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc6f2154e469, moduleTitle=NEJM：采用CRISPR-Cas9进行在体基因编辑治疗转甲状腺素蛋白淀粉样变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc6f2154e469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624975, encodeId=7aaa16249e5c9, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=NEJM：CRISPR-Cas9体内基因编辑治疗转甲状腺素蛋白淀粉样变性, objectType=article, longId=215363, objectId=58cb215363aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58cb215363aa, replyNumber=0, likeNumber=103, createdTime=2021-08-07, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58cb215363aa, moduleTitle=NEJM：CRISPR-Cas9体内基因编辑治疗转甲状腺素蛋白淀粉样变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58cb215363aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624974, encodeId=c7a216249e484, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=热烈庆祝吉适研究壁报在IMCAS Asia大会, objectType=article, longId=214280, objectId=056f2142805b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=056f2142805b, replyNumber=0, likeNumber=69, createdTime=2021-07-17, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=056f2142805b, moduleTitle=热烈庆祝吉适研究壁报在IMCAS Asia大会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=056f2142805b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624973, encodeId=2c0d16249e389, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, objectType=article, longId=211283, objectId=6e722112837b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e722112837b, replyNumber=0, likeNumber=42, createdTime=2021-05-15, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e722112837b, moduleTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e722112837b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624972, encodeId=f37216249e255, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=World Journal of Clinical Cases：依托咪酯与丙泊酚在冠心病患者行非心脏手术中的比较：一项随机临床试验, objectType=article, longId=209878, objectId=e0592098e86c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0592098e86c, replyNumber=0, likeNumber=68, createdTime=2021-04-14, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0592098e86c, moduleTitle=World Journal of Clinical Cases：依托咪酯与丙泊酚在冠心病患者行非心脏手术中的比较：一项随机临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0592098e86c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624971, encodeId=4dec16249e124, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=Prostate Cancer P D：CASC11能够促进前列腺癌细胞的侵袭性, objectType=article, longId=209621, objectId=151320962168, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=151320962168, replyNumber=0, likeNumber=66, createdTime=2021-04-08, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=151320962168, moduleTitle=Prostate Cancer P D：CASC11能够促进前列腺癌细胞的侵袭性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=151320962168)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624970, encodeId=18b716249e015, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=Nat Commun：RNF167靶向降解CASTOR1激活mTORC1促进肿瘤的发生发展, objectType=article, longId=207582, objectId=724720e582cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=724720e582cd, replyNumber=0, likeNumber=173, createdTime=2021-02-26, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=724720e582cd, moduleTitle=Nat Commun：RNF167靶向降解CASTOR1激活mTORC1促进肿瘤的发生发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=724720e582cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624969, encodeId=9806162496946, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=J Clin Oncol：以达雷木单抗联合疗法治疗多发性骨髓瘤的持续性MRD阴性情况（POLLUX和CASTOR）, objectType=article, longId=206596, objectId=62c62065968a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62c62065968a, replyNumber=0, likeNumber=0, createdTime=2021-02-03, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62c62065968a, moduleTitle=J Clin Oncol：以达雷木单抗联合疗法治疗多发性骨髓瘤的持续性MRD阴性情况（POLLUX和CASTOR）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62c62065968a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624968, encodeId=fac816249682d, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=史伟浩：颈动脉APO病变CAS治疗策略, objectType=article, longId=206546, objectId=e728206546bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e728206546bf, replyNumber=0, likeNumber=88, createdTime=2021-02-02, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e728206546bf, moduleTitle=史伟浩：颈动脉APO病变CAS治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e728206546bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624967, encodeId=d5f2162496ede, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=N Engl J Med ：首次！CRISPR-Cas9技术可在人体实验中有效治疗镰状细胞贫血和β-地中海贫血, objectType=article, longId=205010, objectId=cced205010d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cced205010d4, replyNumber=0, likeNumber=77, createdTime=2021-01-01, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cced205010d4, moduleTitle=N Engl J Med ：首次！CRISPR-Cas9技术可在人体实验中有效治疗镰状细胞贫血和β-地中海贫血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cced205010d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624966, encodeId=08501624966b2, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=CRISPR/Cas基因编辑疗法的前景与伦理争议, objectType=article, longId=204596, objectId=c317204596dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c317204596dd, replyNumber=0, likeNumber=78, createdTime=2020-12-18, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c317204596dd, moduleTitle=CRISPR/Cas基因编辑疗法的前景与伦理争议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c317204596dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624965, encodeId=927d1624965a0, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=CRISPR/ Cas9基因编辑疗法全新临床进展, objectType=article, longId=204286, objectId=f54e20428668, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f54e20428668, replyNumber=0, likeNumber=80, createdTime=2020-12-09, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f54e20428668, moduleTitle=CRISPR/ Cas9基因编辑疗法全新临床进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f54e20428668)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624964, encodeId=c856162496432, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=CELL：CRISPR/Cas9编辑人类胚胎可能导致大片段突变, objectType=article, longId=202693, objectId=c7bd20269374, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7bd20269374, replyNumber=0, likeNumber=98, createdTime=2020-11-01, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7bd20269374, moduleTitle=CELL：CRISPR/Cas9编辑人类胚胎可能导致大片段突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7bd20269374)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624963, encodeId=aef516249634c, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=Cell Death Dis：lncRNA CASC9：非小细胞肺癌中吉非替尼耐药性的诱因, objectType=article, longId=202582, objectId=81c72025824a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81c72025824a, replyNumber=0, likeNumber=77, createdTime=2020-10-30, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81c72025824a, moduleTitle=Cell Death Dis：lncRNA CASC9：非小细胞肺癌中吉非替尼耐药性的诱因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81c72025824a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624962, encodeId=c54216249627d, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=Brit J Cancer：晚期前列腺癌中富集的BCAS2蛋白能够与NBS1互作增强DNA双链断裂修复, objectType=article, longId=201776, objectId=46ed201e76a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46ed201e76a5, replyNumber=0, likeNumber=70, createdTime=2020-10-08, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46ed201e76a5, moduleTitle=Brit J Cancer：晚期前列腺癌中富集的BCAS2蛋白能够与NBS1互作增强DNA双链断裂修复, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46ed201e76a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1624961, encodeId=ef721624961ff, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, objectTitle=Br J Cancer：CRISPR/Cas9全基因组功能丧失筛选技术鉴定法尼基蛋白转移酶参与肾细胞癌的舒尼替尼耐药性, objectType=article, longId=201704, objectId=45e8201e0416, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45e8201e0416, replyNumber=0, likeNumber=80, createdTime=2020-10-07, rootId=0, userName=yaanren, userId=411420689333, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45e8201e0416, moduleTitle=Br J Cancer：CRISPR/Cas9全基因组功能丧失筛选技术鉴定法尼基蛋白转移酶参与肾细胞癌的舒尼替尼耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45e8201e0416)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Cas

2020-05-29

yaanren (审核中...)

前往app查看评论内容

#Cas#

巨大淋巴结增生症（Castleman病）

2021-11-07

yaanren (审核中...)

前往app查看评论内容

#Cas#

全球靶向CD19 的ADC药物Loncastuximab tesirine启动关键II期研究，已完成中国临床试验首例患者给药

2021-10-02

yaanren (审核中...)

前往app查看评论内容

#Cas#

case report 第一次投cover letter 有什么建议吗？

2021-08-14

yaanren (审核中...)

前往app查看评论内容

#Cas#

ACAS应该选择BMT还是CEA/CAS？

2021-08-11

yaanren (审核中...)

前往app查看评论内容

#Cas#

NEJM：采用CRISPR-Cas9进行在体基因编辑治疗转甲状腺素蛋白淀粉样变性

2021-08-10

yaanren (审核中...)

前往app查看评论内容

#Cas#

NEJM：CRISPR-Cas9体内基因编辑治疗转甲状腺素蛋白淀粉样变性

2021-08-07

yaanren (审核中...)

前往app查看评论内容

#Cas#

热烈庆祝吉适研究壁报在IMCAS Asia大会

2021-07-17

yaanren (审核中...)

前往app查看评论内容

#Cas#

Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！

2021-05-15

yaanren (审核中...)

前往app查看评论内容

#Cas#

World Journal of Clinical Cases：依托咪酯与丙泊酚在冠心病患者行非心脏手术中的比较：一项随机临床试验

2021-04-14

yaanren (审核中...)

前往app查看评论内容

#Cas#

Prostate Cancer P D：CASC11能够促进前列腺癌细胞的侵袭性

2021-04-08

yaanren (审核中...)

前往app查看评论内容

#Cas#

Nat Commun：RNF167靶向降解CASTOR1激活mTORC1促进肿瘤的发生发展

2021-02-26

yaanren (审核中...)

前往app查看评论内容

#Cas#

J Clin Oncol：以达雷木单抗联合疗法治疗多发性骨髓瘤的持续性MRD阴性情况（POLLUX和CASTOR）

2021-02-03

yaanren (审核中...)

前往app查看评论内容

#Cas#

史伟浩：颈动脉APO病变CAS治疗策略

2021-02-02

yaanren (审核中...)

前往app查看评论内容

#Cas#

N Engl J Med ：首次！CRISPR-Cas9技术可在人体实验中有效治疗镰状细胞贫血和β-地中海贫血

2021-01-01

yaanren (审核中...)

前往app查看评论内容

#Cas#

CRISPR/Cas基因编辑疗法的前景与伦理争议

2020-12-18

yaanren (审核中...)

前往app查看评论内容

#Cas#

CRISPR/ Cas9基因编辑疗法全新临床进展

2020-12-09

yaanren (审核中...)

前往app查看评论内容

#Cas#

CELL：CRISPR/Cas9编辑人类胚胎可能导致大片段突变

2020-11-01

yaanren (审核中...)

前往app查看评论内容

#Cas#

Cell Death Dis：lncRNA CASC9：非小细胞肺癌中吉非替尼耐药性的诱因

2020-10-30

yaanren (审核中...)

前往app查看评论内容

#Cas#

Brit J Cancer：晚期前列腺癌中富集的BCAS2蛋白能够与NBS1互作增强DNA双链断裂修复

2020-10-08

yaanren (审核中...)

前往app查看评论内容

#Cas#

Br J Cancer：CRISPR/Cas9全基因组功能丧失筛选技术鉴定法尼基蛋白转移酶参与肾细胞癌的舒尼替尼耐药性

2020-10-07

科室
- - 订阅+
  - 更多科室
工具
服务